Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) traded up 12.9% on Wednesday . The stock traded as high as C$1.76 and last traded at C$1.75. 62,156 shares changed hands during trading, a decline of 49% from the average session volume of 122,649 shares. The stock had previously closed at C$1.55.
Medicenna Therapeutics Stock Up 1.6 %
The firm’s fifty day moving average price is C$1.49 and its two-hundred day moving average price is C$0.80. The stock has a market cap of C$135.80 million, a price-to-earnings ratio of -8.48 and a beta of 1.16. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.00 and a quick ratio of 4.65.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
Read More
- Five stocks we like better than Medicenna Therapeutics
- What is MarketRank™? How to Use it
- Hasbro’s Management Made All the Right Calls This Quarter
- Industrial Products Stocks Investing
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Learn Technical Analysis Skills to Master the Stock Market
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
